Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT05703919
Recruiting Phase 4

Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease

NCT05703919 · tracked via the Priya Life Science Denmark tracker
Sponsor
Central Denmark Region
Phase
Phase 4
Started
2025-06-02
Last updated
2026-10-02

Condition(s) studied

COPD ExacerbationCOPD Exacerbation Acute

Investigational drug(s) / intervention(s)

Titrated OxygenStandard Oxygen

Titrated Oxygen: Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%

Standard Oxygen: Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators

Study summary

The STOP-COPD trial is a randomized, patient-blinded, prehospital clinical trial designed to evaluate the effect of titrated oxygen therapy compared to standard oxygen treatment in patients with suspected acute exacerbation of chronic obstructive pulmonary disease (AECOPD) treated with inhaled bronchodilators. The primary objective is to determine whether a titrated oxygen strategy targeting SpO₂ 88-92% can reduce 30-day mortality compared to the current standard practice using 100% compressed oxygen as a nebulizer driver.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients over the age of 40 * EMT or Paramedic suspected AECOPD * Confirmed suspicion of COPD Exclusion Criteria: * Bronchospasm due to asthma, allergic reaction or non-COPD conditions * Known or suspected pregnancy * Prehospital Non-invasive, invasive or assisted bag mask ventilation * Allergy to inhaled bronchodilators (Salbutamol) * Inter-hospital transfer * More than 2 doses (5 mg salbutamol) inhalation drug, acute treatment by EMS (emergency medical service) personnel, before allocated treatment is initiated * Suspicion of acute coronary syndrome

Primary outcome measure(s)

  • Mortality, 30-day — Day 30 from randomization
    Vital status assessed 30 days after randomization using hospital electronic medical records

Trial sites (1)

FacilityCityRegionStatus
Prehospital Emergency Medical Servises, Central Denmark Region Aarhus N Denmark Recruiting

More Central Denmark Region trials in Denmark

The Pre-POCT-Non-Conveyance Trial: Prehospital Point-of-Care Testing to Support Non-Conveyance Decisions Recruiting
Prehospital Point-of-Care Hs-Troponin I for Rule-Out of Acute Myocardial Infarction in Patients Without ST-Segment Elevation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05703919 on ClinicalTrials.gov ↗ ← All trials in Denmark